Which Antipsychotic Is Right for Me?

Antipsychotics are prescribed for schizophrenia and bipolar disorder, and at lower doses as add-on treatment for depression. Across the group, large pragmatic trials have generally found the second-generation drugs comparable to one another in effectiveness, with one clear exception: clozapine is more effective in treatment-resistant illness, and carries monitoring requirements that keep it from being a first choice.

What that means in practice is that the decision is dominated by side effects, and by which of them you are least willing to accept. Metabolism has a real but secondary role, mostly in setting the dose.

The indication shapes the field: not every antipsychotic is used for bipolar disorder, and the doses used as an add-on for depression are much lower than those used for psychosis. Treatment history matters even more here than in most classes, because two adequate trials that failed is the specific threshold at which clozapine becomes the evidence-based next step rather than a third similar alternative.

This is the heart of the decision. The main trade-offs are metabolic effects such as weight gain and changes in blood sugar and lipids, movement effects including restlessness, stiffness and the long-term risk of tardive dyskinesia, sedation, and effects on prolactin. The drugs sit in very different places on those axes. One that is sedating may be welcome if sleep is badly disrupted and intolerable if you are trying to work.

Because these are long-term treatments, a side effect you can tolerate for a week but not a year is a genuine reason to choose differently.

Existing diabetes, obesity or cardiovascular disease pushes against the drugs with the heaviest metabolic burden. A history of movement disorders pushes against those most likely to cause them. Some antipsychotics prolong the QT interval, which matters if you have a cardiac history or take other QT-prolonging medications. These constraints usually bind harder than preference does.

Several antipsychotics are available as long-acting injections given every few weeks. For someone who finds daily tablets difficult, that formulation can matter more to the outcome than which molecule is inside it, because consistency of treatment is one of the strongest predictors of staying well.

This is where pharmacogenetics contributes, and its role here is mostly about dose. CYP2D6 clears aripiprazole, brexpiprazole, perphenazine, iloperidone and haloperidol among others, and poor metabolizers reach higher concentrations at a standard dose.^[1] The labelling for several of these drugs already carries a reduced dose recommendation for poor metabolizers, and Dutch guidance makes similar recommendations for haloperidol and zuclopenthixol.^[2]

Unlike statins or opioids, this rarely rules a drug out. It more often means starting lower and titrating more carefully, which is worth knowing before side effects lead to the conclusion that a drug does not suit you.

Most of the older drugs and several second-generation ones are inexpensive generics. Clozapine requires regular blood monitoring, which is a substantial commitment and the main reason it is reserved rather than routine. Long-acting injections require regular appointments. These practical factors legitimately influence what is offered.

Metabolism affects exposure across much of this class, but because the drugs differ so much more in their side-effect profiles than in how they are cleared, genetics tends to fine-tune the dose rather than select the drug.

The useful summary is that a CYP2D6 result here changes how a drug is started rather than whether it is used. That is a smaller claim than in some other classes, and it is the honest one.

It also does not speak to the side effects that most often determine the choice. Weight gain, movement effects and sedation are driven mainly by which receptors a drug acts on, and no pharmacogenetic test currently predicts them well.

The most useful moment is when side effects have appeared at doses most people tolerate, which is consistent with reduced clearance and supports a lower dose rather than abandoning the drug. It is also worth having before starting one of the drugs whose labelling specifies a dose reduction for poor metabolizers, since that adjustment is easier made at the outset.

Set expectations appropriately: a result will not tell you which antipsychotic will control your symptoms, and it will not predict weight gain.

• Abilify Side Effects and Dosing: How CYP2D6 Affects Aripiprazole
• Clozapine (Clozaril) Side Effects: How CYP2D6 Affects Your Dose
• Haloperidol (Haldol) Side Effects: When CYP2D6 Genetics Are Behind Them
• Quetiapine (Seroquel) Side Effects: When CYP3A4 Genetics Make It Harder
• Zuclopenthixol (Clopixol) Side Effects: CYP2D6 Genetics Explained
• How to Read Your GeneSight Report: Green, Yellow, and Red Explained

Clozapine is more effective in treatment-resistant illness, which is why it is the recommended step after two adequate trials have failed. It also requires regular blood monitoring, which is why it is not used first. Beyond that, large pragmatic trials have generally found the second-generation drugs comparable on effectiveness, so side effects usually decide.

Not really. It can tell you how quickly you clear several of them, which informs the starting dose and can explain side effects that appear at ordinary doses. It does not predict the side effects that most often drive the choice, such as weight gain and movement effects, and it does not predict symptom response.

Metabolic side effects vary substantially between these drugs and between people, but they are driven mainly by which receptors a drug acts on rather than by the metabolising genes in a standard pharmacogenetic panel. If weight gain is a problem, the productive conversation with your prescriber is about which drug rather than about dose.

There are several possible reasons, including the indication, since add-on treatment for depression uses much lower doses than treatment for psychosis. Reduced CYP2D6 metabolism is another: several labels specify a reduced dose for poor metabolizers, so a lower dose can be the correct one for you.